Pediatric Thromboelastograph 6s and Laboratory Coagulation Reference Values. 2021

Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
From the Department of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, Massachusetts (Moynihan).

Specific reference intervals (RIs) facilitate accurate interpretation of results. Coagulation assay results may vary by demographics and also between reagents and analyzers used. Current Thromboelastograph 6s (TEG 6s) Hemostasis Analyzer RIs were generated from adult samples. To generate reagent analyzer-specific pediatric RIs for TEG 6s and coagulation parameters. A prospective, observational, single-center study of healthy children undergoing general anesthesia (January 3, 2017 to January 3, 2019). Venous blood samples were obtained for TEG 6s (Kaolin, Kaolin-Heparinase, Rapid and Functional Fibrinogen assays) and coagulation parameters (activated partial thromboplastin time, prothrombin time, thrombin clotting time, Echis time, antithrombin activity, and fibrinogen concentration using Instrumentation Laboratory ACL-TOP analyzers). Differences between activated partial thromboplastin time and prothrombin time reagents were investigated using mixed-effects regression, comparing maximum coefficients-of-variation with assay-specific allowable variation. RIs (lower/upper limits 2.5th of 97.5th percentiles) were generated using the following 2 methods: within discrete age-groups (neonates [<1 month], infants [1 month-1 year], young children [1-5 years], older children [6-10 years], and adolescents [11-16 years]), and modeled as functions of age and/or sex using quantile regression, including significant fractional polynomial and interaction terms. Variation between prothrombin time and activated partial thromboplastin time assays using different reagents was clinically significant. Reagent-analyzer specific pediatric RIs were generated using data from 254 children. Discrete and model-based RIs varied by age for all coagulation parameters and TEG 6s variables in all assays. We report reagent-analyzer specific pediatric RIs for TEG 6s and coagulation parameters. Observed variation reinforces recommendations for laboratory-specific RIs. These findings improve accuracy of interpretation of clinical results, provide a foundation for comparison and validation of tests in pathology, and illustrate feasibility and advantages of model-based RI approaches.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
October 1987, Casopis lekaru ceskych,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
October 1987, Casopis lekaru ceskych,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
October 1957, Archivio "de Vecchi" per l'anatomia patologica e la medicina clinica,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
January 1993, The New England journal of medicine,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
August 1980, Schweizerische medizinische Wochenschrift,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
February 2006, East African medical journal,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
March 1990, Mayo Clinic proceedings,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
July 1985, Vestnik dermatologii i venerologii,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
April 1986, Laboratory animal science,
Katie M Moynihan, and Kerry Johnson, and Mark Rane, and Andrew Norman, and Susan Humphreys, and Christian Stocker, and Kristen Gibbons, and John Roy
January 2015, Journal of medical biochemistry,
Copied contents to your clipboard!